Skip to content
Menu

Piloto

1263 posts

Posts (1263)

Piloto AMPE 5 years ago #1251

Buy. Tomorrow will be late: check this

WHO recommends doctors not use remdesivir to treat COVID-19; GILD -1.6%

Nov. 19, 2020 7:24 PM ETGilead Sciences, Inc. (GILD)By: Jason Aycock, SA News Editor27 Comments
The World Health Organization is recommending against doctors using Gilead Sciences' (NASDAQ:GILD) remdesivir (Veklury) to treat hospitalized COVID-19 patients.
Gilead shares are down 1.6% after hours.
“There is currently no evidence that it improves survival or the need for ventilation,” a panel of experts convened by WHO says in The BMJ.
That comes very shortly after regulators gave the drug a quick approval for treating COVID-19 - and its use in treating President Trump when he was diagnosed with COVID-19 early last month.
A global WHO-sponsored trial, Solidarity, found that the drug didn't reduce deaths, and the experts reviewed data from three other trials to conclude remdesivir has "no meaningful effect" on time to clinical improvement.

Piloto FCEL 6 years ago #1252

Only option to the the oil industry is to diversify and FCEL I good spot with heavy fix assets. The future is unlimited . If but BO this will flight higher

Piloto HTBX 6 years ago #1255

Htbx working with Merck in a pill solution. Patience !

Piloto VXRT 6 years ago #1256

Guys, Merck is working on a pill vaccine for COVID 18 and nothing to do with VXRT which has not moved from the start. I made money with this stock and now is dead . See better SRNO , Heat Biologist , AMPE, Merck.

Piloto IBIO 6 years ago #1257

Why losers keep talking about politics. Move on.

Piloto HTBX 6 years ago #1258

All other vaccines in jeopardy . T cells the most promising, no selling until $13.00 each

Piloto HTBX 6 years ago #1259

NEW FINDINGS ABOUT SEVERE COVID PROGRESSES Clotted blood in Corona - antibodies are to blame!

November 8th, 2020 - 1:07 pm
Corona crisis: all information
New findings about SARS-CoV-2: Not the virus itself, but the antibodies that the body forms in the event of a corona infection are to blame for severe Covid-19 courses!

Researchers at the University of Michigan have now discovered that this is an autoimmune reaction of the body's own defenses, in which special antibodies are formed. These in turn attack your own system, more precisely the white blood cells.

"In patients with Covid-19 we see a relentless, self-reinforcing vicious circle of inflammation and clumping of the blood throughout the body," explains scientist Yogendra Kanthi. To find out whether the strong tendency to thrombosis is due to an effect similar to that of an autoimmune disease, the scientists examined the blood of 172 corona patients with severe disease.

In antiphospholipid syndrome, the body makes antibodies against components of the blood. The researchers looked for these typical antibodies in the analyzed blood samples.

About half of the Covid-19 patients had at least one of these auto-antibodies. A quarter of the patients showed two or more antibodies. Particularly noticeable: the higher the titer, the more severe the damage to organs such as the kidneys and lungs.

The scientists have great hope that their findings will soon be of great use in the treatment of Covid-19. The antiphospholipid syndrome is treated with the active ingredient dipyridamole, among other things, and initial tests show that this could also be effective in corona diseases

Piloto HTBX 6 years ago #1260

I only anticipate a BO. No way this company is not on the eyes of big pharma . Read what is going on in Europe :

UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials

OXFORD, United Kingdom and MARLBOROUGH, Mass., October 22, 2020 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it has been selected to provide T cell testing to the UK Vaccines Taskforce, a body formed by the UK Government to assess the suitability of vaccines for use in the UK population. Oxford Immunotec was chosen in this competitive process for its expertise in T cell measurement and its unique ability to provide T-SPOT® technology, the only globally regulated ELISPOT platform, currently used clinically for identifying T cells made in response to another respiratory pathogen responsible for Tuberculosis. The award includes the measurement of the magnitude of the SARS-CoV-2 protein-specific T cell response using the company’s new T-SPOT® Discovery SARS-CoV-2 assay and is recognition of the company’s ability to deliver clinical grade, consistent and reproducible diagnostic products.

T cells are becoming increasingly recognised for their role in SARS-CoV-2 infection and immunity; measuring the presence and size of any T cell response can give adjunctive information to that available by serology. Consequently, the UK Vaccines Taskforce is including T cell analysis in COVID vaccine trials.